This Phase 2 trial looked at a new way to give the drug mosunetuzumab for follicular lymphoma. Ninety-four patients received the drug under the skin, while ninety others received the same drug through an IV line. Both groups had already tried at least two other treatments.
The study measured how well the drug worked and how patients tolerated it. Results showed that the subcutaneous version led to an overall response rate of 76.6 percent and a complete response rate of 61.7 percent. The median duration of complete response was 34.6 months, and median progression-free survival was 23.7 months.
Safety was a major focus. The subcutaneous form caused cytokine release syndrome events in 29.8 percent of patients, compared to 44.4 percent with the IV form. Severe events, defined as grade 2 or higher, occurred in 9.6 percent of the subcutaneous group versus 18.9 percent of the IV group. The primary analysis focused on pharmacokinetic endpoints, which confirmed non-inferiority between the two methods.
Because this is a Phase 2 study, the findings are early and need more confirmation. The subcutaneous route offers a potentially easier administration option with a favorable safety profile compared to the IV comparator.
